FIELD: biotechnology.
SUBSTANCE: invention relates to methods, pharmaceutical compositions and sets for treating or mitigating the effects of a cancer in an individual that has an atypical BRAF mutation (i.e., a BRAF non-V600E/K mutation) comprising an ERK inhibitor. Also the methods of identifying an individual having a cancer with an atypical BRAF mutation who would benefit from a therapy comprising an ERK inhibitor are provided.
EFFECT: obtaining compositions and methods of treatment of cancer with BRAF atypical mutations.
68 cl, 4 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING MALIGNANT TUMORS USING COMBINATIONS OF ERK AND RAF INHIBITORS | 2014 |
|
RU2722784C2 |
| METHOD FOR OBTAINING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES | 2018 |
|
RU2795970C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| MULTISPECIFIC BINDING PROTEINS WITH MUTANT DOMAINS FAB | 2019 |
|
RU2827657C2 |
| METHOD FOR PRODUCTION OF ARENAVIRUS, AS WELL AS ARENAVIRUS MUTANTS WITH ANTITUMOR PROPERTIES | 2019 |
|
RU2812046C2 |
| MUTANT POLYPEPTIDE HYDROXYPHENYLPYRUVATE DIOXYGENASE, CODING GENE THEREOF AND USE THEREOF | 2019 |
|
RU2822892C1 |
| NOVEL VERSIONS OF INTERLEUKIN-2 FOR TREATING CANCER | 2020 |
|
RU2833537C2 |
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
